Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RGS12 | O14924 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231627 | 1.00 | MAPT (0.59) | MAPTTSHRGAAKDM4EPOLB | |
| Nitric Acid SCHEMBL7984255 | 0.97 | MAPT (0.56) | MAPTTSHRGAAKDM4EPOLB | |
| SCHEMBL7564083 | 0.88 | POLB (0.52) | MAPTTSHRGAAKDM4EPOLB | |
| SCHEMBL6379699 | 0.86 | GAA (0.59) | MAPTTSHRGAAKDM4EPOLB | |
| SCHEMBL2434953 | 0.86 | GAA (0.59) | MAPTTSHRGAAKDM4EPOLB | |
| SCHEMBL1865824 | 0.86 | CASP6 (0.55) | MAPTTSHRGAAKDM4EPOLB | |
| SCHEMBL2742575 | 0.85 | MAPT (0.58) | MAPTTSHRKDM4EPOLBHPGD | |
| SCHEMBL13520189 | 0.85 | POLB (0.52) | MAPTTSHRKDM4EPOLBHPGD | |
| SCHEMBL7126615 | 0.85 | POLB (0.52) | MAPTTSHRKDM4EPOLBHPGD | |
| SCHEMBL3533309 | 0.83 | POLB (0.51) | MAPTTSHRKDM4EPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122050846-A | Ischemic cerebral apoplexy risk assessment model fusing environmental exposure histology and metabonomics biomarkers and model construction method | 生态环境部华南环境科学研究所(生态环境部生态环境应急研究所) | 2026-05-15 | — | — | CN | disclosed |
| US-12577266-B2 | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4707404-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2026044019-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA INFECTION | LOW STEWART (US) | 2026-02-26 | — | — | WO | disclosed |
| US-12559511-B2 | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3492919-B1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250339516-A1 | METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES | VACCINVENT GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250326863-A1 | METHOD AND MEANS FOR ENHANCING THERAPEUTIC ANTIBODIES | VACCINVENT GMBH (DE) | 2025-10-23 | — | — | US | disclosed |
| US-20250270311-A1 | METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES | VACCINVENT GMBH (DE) | 2025-08-28 | — | — | US | disclosed |
| US-20250177506-A1 | VACCINATION AND ANTIBODY GENERATION PLATFORM | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-06-05 | — | — | US | disclosed |
| EP-1144393-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR | AstraZeneca AB (SE) | 2001-10-17 | — | — | EP | disclosed |
| EP-1133484-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001055141-A1 | AZINE DERIVATIVES AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055144-A1 | ISOTHIAZOLE DERIVATIVES AND THEIR USE AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055142-A1 | ISOTHIAZOLE DERIVATIVES AND THEIR USE AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055139-A1 | ISOTHIAZOLE DERIVATIVES AND THEIR USE AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055145-A1 | AZINE DERIVATIVES AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000005223-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000005224-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR | ASTRAZENECA AB (SE) | 2000-02-03 | — | — | WO | disclosed |
| US-5639457-A | INTRODUCING DNA SEQUENCE CODING FOR REARRANGED ANTIBODY INTO MALE PRONUCLEUS OF FERTILIZED OVUM; IMPLANTING IN PIG OR RABBIT; TRANSGENIC OFFSPRING PRODUCE ANTIBODIES | Brem, Gottfried (DE) | 1997-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339516-A1 | METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES | CD22, FCGR3B, FCGR2A | MAPT 4255/4885TSHR 2370/4885GAA 1985/4885 |
| US-12559511-B2 | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens | PTMS, MKI67, ACP1 | MAPT 4744/4885TSHR 1086/4885GAA 2180/4885 |
| US-20250326863-A1 | METHOD AND MEANS FOR ENHANCING THERAPEUTIC ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | MAPT 265/4885TSHR 1125/4885GAA 756/4885 |
| US-12577266-B2 | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens | ACP1, AOX1, PTMS | MAPT 4401/4885TSHR 1381/4885GAA 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.